Company
Business+Science
Our vision is to connect business and science to help each unique organization perform at its best. Our cloud-based tools help life sciences teams plan, monitor, analyze and ultimately manage performance across their R&D portfolios and corporations.
R&D Logic, Inc. is a privately held company whose management team has extensive industry experience. R&D Logic received its initial capital from Tenex Medical Investors group, institutional and other private investors.
Trusted by the industry
Our customer base includes life sciences companies at all stages of growth.
Two decades in business
Our leaders are industry veterans and the majority of our team members have been with us for over a decade..
Deep expertise
For biotech and life science professionals, the following statement won’t be a surprise: the life science industry is unique in its complexity.
Introducing our next-gen solution suite offering role-based graphical dashboards with Business Intelligence capabilities.
From R&D tax credits to the high risk of innovation to decades long product life cycles, the life science industry is like no other.
Time is money or any other commodity we care to translate it into, but the brutal truth is that it's the only resource we cannot recycle.
Your FP&A processes should sit on top of all your systems, creating an outlook that aligns with your past and present performance.
There's nothing really big about data unless you can convert it into information, then gather insight, and create knowledge.
High performance arises from fostering and leveraging the interdependence of roles in R&D-intensive environments..
Tracking time in R&D has two key dimensions: the time that’s going in and the time it takes to see results.
Experienced Founder
Wanda Ionescu
Founder and CEO
Wanda has extensive experience and in-depth technical expertise, having pioneered early internet technology that became one of the first web-based transactional systems for the R&D industry. Prior to founding R&D Logic, Wanda ran a premier consulting firm focused on architecting, developing and implementing business and scientific system solutions to address complex life sciences requirements. Wanda holds a MS in Computer Science and an MBA in Economic Cybernetics from Academy Of Sciences Bucharest, Romania.
Our News
November 2025
Aura Biosciences is leveraging a novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications with an initial focus on ocular and urologic oncology.
September 2025
The team at Profound Therapeutics is making profound impacts on their understanding of biology and disease, empowering them to create therapeutics that would not have previously been possible – another step closer to making a profound impact on human health.
September 2025
Adverum is driven to establish gene therapy as a new standard of care for the leading causes of vision loss.
September 2025
Oxford BioTherapeutics is dedicated to pioneering the next generation of oncology treatments through targeted therapies, including Antibody-Drug Conjugates (ADC), Immuno-oncology, T-Cell Engagers (TCE), and radiopharmaceuticals.
March 2025
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins by creating a platform that designs small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable.
December 2024
Prime Medicine™ was founded with a goal of transforming the lives of patients with debilitating diseases through the application of our groundbreaking Prime Editing platform and technology.
August 2024
Ohalo’s breakthrough technology, Boosted Breeding, will usher in a new era of improved agricultural productivity to radically transform global agriculture.
July 2024
Arena BioWorks is focused on human biology, with a mission to understand mechanisms of disease in the context of human physiology and to translate those insights into new medicines that impact human health.
May 2024
Jasper is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases.
March 2024
C4 Therapeutics is dedicated to delivering on the promise of targeted protein degradation (TPD) to create a new generation of medicines that transforms patients’ lives.
January 2024
Karuna is a biopharmaceutical company driven to discover, develop and deliver transformative medicines for people living with psychiatric and neurological conditions.
August 2023
Protego Biopharma focuses on the discovery and development of first- or best-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various systemic amyloid diseases, such as light chain (LC) amyloidosis.
August 2023
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.
For earlier news, view our news archive.